pharma · Rectal Cancer
Changhai Hospital
Changhai Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Rectal Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
serplulimab、bevacizumab
Phase 3 · small molecule · Rectal Cancer
serplulimab、bevacizumab for Rectal Cancer is a Phase 3 program (small_molecule) at Changhai Hospital with 1 ClinicalTrials.gov record(s).
Internal code CHOICE IV
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Changhai Hospital
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Rectal Cancer
- Status
- active
- Trials
- 1